Drug Safety 2018

SMi Group11 - 12 June 2018, London, UK.
SMi Group are delighted to announce their 5th Drug Safety conference. For drugs anywhere, it's the safety in patients which is a huge issue, constantly under surveillance, irrespective of where the drug is in its pipeline.

The Global Pharmaceutical Market currently has a market value of $1057 billion. If a drug is found to be unsafe, causing serious side effects, it can have a huge knock on effect on revenue, causing huge losses to pharmaceutical companies manufacturing the drug.

Drug Safety 2018 aims to discuss the latest findings and current thinking on pharmacovigilance. Importantly, it will address the newest regulatory updates and interpretations of them, including the impact of the vital and much awaited Clinical Trial Regulations.

Network and learn from leading professionals such as:

Keynote Speakers

  • David Lewis, Senior Adviser Pharmacovigilance, CMO Patient Safety, Novartis
  • Peter De Veene, Senior Vice President and Head Global Drug Safety and QPPV, Grünenthal
  • Simon Ashworth, VP EU QPPV, EU Head Compliance and Marketed Products and Head PV Affiliate Relations, Takeda

Regulatory Speaker

  • Kirsty Wydenbach, Deputy Unit Manager, Clinical Trials Unit, MHRA

Pharmaceutical Speakers:

  • John Solomon, Head of Pharmacovigilance-UK & Ireland, Sanofi
  • Bjarke Naver, Head of Pharmacovigilance Science, LEO Pharma
  • Sue Rees, EU QPPV, Executive Director, Global Safety, Amgen
  • Jackie Roberts, Executive Director Regulatory, Pharmacovigilance and Medical UK/IE/Malta and MENA, Accord Healthcare
  • Philip Eichorn, Senior Director, Worldwide Safety and Regulatory, Pfizer
  • Rawya Al Kredly, Director of Medical Affairs Department, Gulf Pharmaceutical Industries (Julphar)
  • Bert van Leeuwen, Deputy QPPV, Astellas
  • Kashif Sheikh, Safety Surveillance Specialist, Novo Nordisk

Featured Highlights:

  • MHRA spotlight presentation on the future of Clinical Trial Regulations
  • Hear first experiences with the new Eudravigilence system
  • Gain insight into how competitors are reporting adverse effects under the new legislation and system
  • Discuss risk-minimisation and signal detection strategies with industry-thought leaders
  • Evaluate the benefits and pitfalls of patient involvement and patient support programs

For further information and to register, please visit:
http://www.drugsafetyconference.co.uk/wpn

Early-Bird Rates

  • Book by 28th February and save £400
  • Book by 29th March and save £200
  • Book by 30th April and save £100

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Sanofi and GSK sign agreements with the Government…

Sanofi and GSK have signed agreements with the Government of Canada for the supply of up to 72 million doses of an adjuvanted COVID-19 vaccine, beginning in 2021. Thom...

BioNTech and Pfizer initiate rolling submission to…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lea...

Johnson & Johnson initiates pivotal global Pha…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, J...

Scientists trace severe COVID-19 to faulty genes a…

More than 10 percent of young and healthy people who develop severe COVID-19 have misguided antibodies that attack not the virus, but the immune system itself, new resear...

Vir Biotechnology and GSK announce global expansio…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Eff...

Johnson & Johnson announces European Commissio…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Pur...

Johns Hopkins researchers publish COVID-19 'predic…

Using a combination of demographic and clinical data gathered from seven weeks of COVID-19 patient care early in the coronavirus pandemic, Johns Hopkins researchers today...

Web resources bring new insight into COVID-19

Researchers around the world are a step closer to a better understanding of the intricacies of COVID-19 thanks to two new web resources developed by investigators at Bayl...

COVID-19 vaccine AZD1222 clinical trial resumed in…

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). ...

COVID-19 Long-Acting AntiBody (LAAB) combination A…

AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside th...

Adequate levels of vitamin D reduces complications…

Hospitalized COVID-19 patients who were vitamin D sufficient, with a blood level of 25-hydroxyvitamin D of at least 30 ng/mL (a measure of vitamin D status), had a signif...

Protective antibodies persist for months in surviv…

People who survive serious COVID-19 infections have long-lasting immune responses against the virus, according to a new study led by researchers at Massachusetts General ...